Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

189 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Full realization of the RIBLL2 separator at the HIRFL-CSR facility.
Xu XD, Zheng Y, Sun ZY, Song YN, Sun BH, Terashima S, Wang CJ, Guo G, Li GS, Wei XL, Xu JY, Zhang JC, Cao Y, Gao BS, Han JX, Liu JR, Lu CG, Jin SY, Ong HJ, Qi HT, Qin Y, Sun YZ, Tanihata I, Wan LP, Wang KL, Wang ST, Wang XX, Wu TY, Wu XT, Zhang MX, Zhang WW, Zhang XB, Zhang XH, Zhao JW, Zhou ZC, Zhu LH. Xu XD, et al. Among authors: han jx. Sci Bull (Beijing). 2025 Jan 18:S2095-9273(25)00044-1. doi: 10.1016/j.scib.2025.01.020. Online ahead of print. Sci Bull (Beijing). 2025. PMID: 39880785 No abstract available.
Protease-activated receptor 1 in the pathogenesis of cystic fibrosis.
Sarkar S, Han JX, Azzopardi K, Dhar P, Saeed MA, Day S, Ranganathan S, Sutton P. Sarkar S, et al. Among authors: han jx. BMJ Open Respir Res. 2025 Jan 19;12(1):e002960. doi: 10.1136/bmjresp-2024-002960. BMJ Open Respir Res. 2025. PMID: 39832889 Free article.
Energy-Transfer Enabled 1,4-Aryl Migration.
Wen SY, Chen JJ, Zheng Y, Han JX, Huang HM. Wen SY, et al. Among authors: han jx. Angew Chem Int Ed Engl. 2025 Jan 15;64(3):e202415495. doi: 10.1002/anie.202415495. Epub 2024 Nov 20. Angew Chem Int Ed Engl. 2025. PMID: 39498962
Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium.
Han JX, Koh MJ, Boussi L, Sorial M, McCabe SM, Peng L, Singh S, Eche-Ugwu IJ, Gabler J, Fernandez Turizo MJ, MacVicar CT, Garg A, Disciullo A, Chopra K, Lenart A, Nwodo E, Barnes J, Koh MJ, Miranda E, Chiattone C, Stuver R, Horwitz SM, Merrill M, Jacobsen E, Manni M, Civallero M, Skrypets T, Lymboussaki A, Federico M, Kim Y, Kim JS, Cho JY, Eipe T, Shet T, Sridhar E, Shetty A, Saha S, Jain H, Sengar M, Van Der Weyden C, Prince HM, Hamouche R, Murdashvili T, Foss F, Gentilini M, Casadei B, Zinzani PL, Okatani T, Yoshida N, Yoon SE, Kim WS, Panchoo G, Mohamed Z, Verburgh E, Alturas JC, Al-Mansour M, Ford J, Cabrera ME, Ku A, Bhagat G, Ma H, Sawas A, Kariya KM, Iwasaki M, Bhanushali F, O'Connor OA, Marchi E, Shen C, Shah D, Jain S. Han JX, et al. Blood Adv. 2025 Feb 11;9(3):583-602. doi: 10.1182/bloodadvances.2024014674. Blood Adv. 2025. PMID: 39481087
189 results